Suppr超能文献

在冠状动脉旁路移植术中输注去甲肾上腺素可改善血小板聚集:一项随机对照试验。

Intraoperative infusion of noradrenaline improves platelet aggregation in patients undergoing coronary artery bypass grafting: a randomized controlled trial.

机构信息

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

出版信息

J Thromb Haemost. 2019 Apr;17(4):657-665. doi: 10.1111/jth.14408. Epub 2019 Mar 11.

Abstract

Essentials Strategies to improve platelet function may reduce excessive bleeding during cardiac surgery. Patients were randomized to standard care or standard care + noradrenaline infusion. Low-dose noradrenaline improved intraoperative platelet aggregation and clot formation. Noradrenaline may be considered to improve intraoperative hemostasis during cardiac surgery. SUMMARY: Background New approaches to prevent bleeding complications during cardiac surgery are needed. Objective To investigate if noradrenaline (NA) enhances platelet aggregation in patients undergoing coronary artery bypass grafting (CABG). Patients/Methods Twenty-four patients undergoing coronary artery bypass grafting (CABG) were included in a prospective parallel-group randomized study. All patients but one were treated with acetylsalicylic acid (ASA). In the treatment group (n = 12), mean arterial blood pressure (MAP) was maintained at pre-induction levels by NA infusion. In the control group (n = 12), NA was administered only if MAP decreased below 60 mmHg. Platelet aggregation (impedance aggregometry with ADP, arachidonic acid [AA] and thrombin-receptor activating peptide [TRAP] as initiators) and clot formation (clotting time, clot formation time and maximum clot firmness by EXTEM, INTEM and FIBTEM tests with thromboelastometry) were assessed before and 50 min after anesthesia induction (before cardiopulmonary bypass was initiated). Results All patients in the treatment group received NA (median dose after 50 min 0.09 (range 0-0.26) μg kg  min ). Four patients in the control group also received NA (0.03-0.12 μg kg  min ). There were differences between the treatment group and the control group in ADP- and AA-induced aggregation changes (ADP, +16 [25th-75th percentiles, 5-26] vs. -7 [-19 to -1] U; AA, +12 [-4 to 16] vs. -9 [-13 to 1] U). INTEM maximum clot firmness increased in the treatment group but not in the control group. Conclusion Infusion of clinically relevant doses of NA enhanced platelet aggregation and clot firmness in ASA-treated CABG patients. NA infusion is hence a potential new method to acutely improve platelet reactivity in patients on antiplatelet therapy undergoing surgery.

摘要

在心脏手术中,改善血小板功能的基本策略可能会减少过度出血。患者被随机分配至标准治疗或标准治疗+去甲肾上腺素输注。小剂量去甲肾上腺素可改善术中血小板聚集和凝块形成。去甲肾上腺素可考虑用于改善心脏手术中的术中止血。

背景

需要新的方法来预防心脏手术中的出血并发症。

目的

研究去甲肾上腺素(NA)是否增强行冠状动脉旁路移植术(CABG)患者的血小板聚集。

患者/方法:24 例拟行冠状动脉旁路移植术(CABG)的患者被纳入前瞻性平行组随机研究。除 1 例患者外,所有患者均接受乙酰水杨酸(ASA)治疗。在治疗组(n=12)中,通过去甲肾上腺素输注将平均动脉血压(MAP)维持在诱导前水平。在对照组(n=12)中,仅在 MAP 下降至 60mmHg 以下时给予去甲肾上腺素。在麻醉诱导前(在开始体外循环之前)和麻醉诱导后 50 分钟时,通过阻抗聚集法(用 ADP、花生四烯酸(AA)和血栓素受体激活肽(TRAP)作为启动剂)评估血小板聚集(ADP、AA 和血栓素受体激活肽)和凝块形成(用 EXTEM、INTEM 和 FIBTEM 试验通过血栓弹性描记术评估凝血时间、凝块形成时间和最大凝块硬度)。

结果

治疗组所有患者均接受去甲肾上腺素治疗(50 分钟后中位数剂量 0.09(范围 0-0.26)μg/kg/min)。对照组有 4 例患者也接受了去甲肾上腺素治疗(0.03-0.12μg/kg/min)。与对照组相比,ADP 和 AA 诱导的聚集变化存在差异(ADP,+16[25-75 百分位,5-26]vs.-7[-19 至-1]U;AA,+12[-4 至 16]vs.-9[-13 至 1]U)。治疗组 INTEM 最大凝块硬度增加,但对照组没有增加。

结论

输注临床相关剂量的去甲肾上腺素可增强接受 ASA 治疗的 CABG 患者的血小板聚集和凝块硬度。去甲肾上腺素输注是一种有潜力的新方法,可以在接受手术的抗血小板治疗患者中急性改善血小板反应性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验